Palbociclib’s therapeutic benefits for breast cancer may be hindered by higher Ki-67 expression, primary resistance to ETs, liver metastases, multiple metastatic sites, later line of therapy, and the use of fulvestrant instead of aromatase inhibitors. This evidence concerns the gene CYP19A1 and breast carcinoma.